Last updated on November 2017

A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Liver Transplant


Brief description of study

A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected with Chronic HCV who have Advanced Liver Disease or are Post-Liver Transplant

Detailed Study Description

To explore the antiviral efficacy of combination therapy with sofosbuvir/ledipasvir fixed-dose combination ribavirin for 12 or 24 weeks in patients with advanced liver disease. Study designed with A cohort and B cohort.

Clinical Study Identifier: TX83931

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Nancy Kelly, RN

Baylor Scott & White Research Institute
Dallas, TX USA
  Connect »